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ABSTRACT  
The present review discusses about RNA interference (RNAi) and its significance in gene therapy. The review mainly focuses on small 
interference RNA (siRNA) as a mediator of RNAi, its therapeutic benefits and various formulation strategies employed to overcome siRNA 
delivery hurdles. RNAi is a regulatory process which occurs endogenously within the cell wherein short double-stranded RNA (siRNA) effects 
sequence-specific posttranscriptional gene silencing. Even though siRNA assists researchers with its powerful therapeutic benefits, there are 
significant hurdles in developing efficient delivery systems for its systemic administration. These are extracellular and intracellular barriers for 
siRNA delivery. The present review addresses about pros and cons of gene therapy and superior advantages provided by siRNA over plasmid 
DNA in gene therapy. It also discloses about the discovery, mechanism of action, significance and applications of siRNA based gene therapies, 
challenges in its delivery and strategies for overcoming delivery hurdles. Furthermore, emphasis is provided on viral and non – viral vector 
based siRNA delivery and the significance of lipid based siRNA delivery, the lipoplexes over polymer based siRNA delivery - the polyplexes, 
followed by recent advances in siRNA based technologies directed against variety of diseases.  
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1. Gene therapy1 
Gene therapy is vital approach employed to treat diseases 
characterized by abnormal genetic function. Gene therapy 
cures dysfunctional cellular processes by either modifying 
the expression of a gene or by correcting an abnormal gene 
in the genome of a cell. Unlike traditional pharmaceuticals, 
gene therapy has the potential to treat almost any disease. 
Gendicine, a recombinant Adenoviruses-p53 gene therapy 
for head and neck squamous cell carcinoma was first 
approved as a commercial gene therapy medicine in 2003.2, 3 
1.1 Need for gene therapy1 
There are varied types of diseases characterized by 
intracellular events that are controlled by specific gene 
transcription and mRNA translation. The alteration in these 
processes lead to the production of proteins which play vital 
role in inducing pathophysiological disorders. Best example 
that requires attention is production of Amyloid protein 
entanglements responsible for memory lost in Alzheimer’s 
disease.4-6 Similarly, production of various intracellular 
messenger proteins inducing cell division play key role in 
neoplastic progression. Pathological proteins responsible for 
age induced macular degeneration7 and neoplastic 
angiogenesis (vasoactive endothelial growth factors)7-13 are 
considered as macromolecules which are synthesized 
intracellularly during mRNA translation process. Hence, any 
change in the normal routine process whether in the 
transcription and/or translation produces drastic changes 
intracellularly which then lead to fetal abnormalities. Gene 
therapy is aimed at treating such pathophysiologies both at 
transcription and translation level with higher probability of 
success compared to conventional therapies. 
1.2 Hurdles in gene therapy1, 14 
There are many delivery hurdles that have prevented gene 
therapy from its widespread use for the effective treatment 
of various diseases. Some of these hurdles are listed as 
under: 
1.2.1 Limited membrane permeability of nucleic acids: 
Since DNA, siRNA, and other nucleic acids are hydrophilic 
and negatively charged macromolecules, they cannot 
efficiently cross cell plasma membrane which is essentially 
composed of hydrophobic lipid bilayer and typically have a 
net negative charge. While naked DNA can be introduced into 
cells through physical methods such as Electroporation,15, 16 
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a gene gun,17 ultrasound,18, 19 or direct injection into target 
tissue,20 the clinical relevance of these methods is limited. 
1.2.2 Short-lived nature of gene therapy: 
Before gene therapy can become a permanent cure for a 
disease, the therapeutic RNA introduced into target cells 
must remain functional and the cells containing the 
therapeutic nucleic acid must be long lived and stable. 
Problems with integrating therapeutic nucleic acid into the 
genome and the rapidly dividing nature of many cells 
prevent gene therapy from achieving long-term benefits. 
1.2.3 Immune response: 
 When any xenobiotic (foreign material viz. siRNA) is 
introduced into human tissue, the immune system attacks 
the invader, often reducing gene therapy effectiveness. 
Furthermore, the immune system’s enhanced response to 
previous treatments makes it difficult for the repeat gene 
therapy in same group of patients. 
1.2.4 Multigene disorders: 
Conditions or disorders that arise from mutations in a single 
gene are the best candidates for gene therapy. Unfortunately, 
some of the most commonly occurring disorders such as 
heart disease, arthritis, diabetes, vasculature, and 
alzheimer’s diseases are caused by the combined effects of 
variations in many genes. Multigene or multifactorial 
disorders such as these would be difficult to treat effectively 
today using gene therapy.  
2. Birth of siRNA 
2.1 Historical development of RNA interference:   
The phenomenon of small interference RNA was first 
observed in plants in 1989.21 Post-transcriptional gene 
silencing by RNA interference, popularly known as RNAi, is a 
phenomenon that is exploited by cells to conduct gene 
regulation. The uniqueness and impact of this discovery can 
be judged from its mechanism22 and the fact that the initial 
discovery was done in the 1990s. In 1998, “breakthrough of 
the year” declared by the Science magazine and the Nobel 
Prize for Medicine or Physiology was jointly awarded to its 
discoverers, Andrew Fire and Craig Mello in 2006. 
2.2 Definition 
RNA interference is the phenomenon by which post 
translational potency of messenger RNA is lost by silencing 
action of complementary single stranded RNA. Mediators of 
RNA interference are small interfering RNA (siRNA),23 
microRNA (miRNA),24-28 Short hairpin (shRNA). However, 
shRNA produces more stable transfection as compared to 
siRNA. 
3. Molecular mechanism of small interference RNA 
in gene silencing7 
In mammalian cell, siRNA is generated by the cleavage of 
larger double-stranded RNA (dsRNA) precursors by the 
RNAse III endonuclease Dicer.29 Dicer is complexed with the 
TAR-RNA binding protein (TRBP) and hands off siRNA to the 
RNA-induced silencing complex (RISC). RISC contains the 
protein that carries out the silencing activity by cleaving the 
target mRNA molecule between bases 10 and 11 relative to 
the 5' end of the antisense siRNA strand. In the core of RISC 
lies the Argonaute (Ago)30 family members and in humans, 
Ago-2(previously known as eIF2C2) carries out the catalytic 
cleavage activity. It has been observed that although the 
siRNA transferred to RISC are double stranded, Ago-2 
cleaves and releases the “passenger” strand, leading to an 
activated form of RISC that contains a single-stranded 
“guide” RNA molecule. It is this guide RNA molecule that 
confers the specificity to the RISC and helps it in target 
recognition by intermolecular base pairing. Ago-2 is 
composed of three domains: PAZ, MID, and PIWI31 domains. 
The function of PAZ and MID domains are docking and 
anchoring the RNA. PIWI domain is the one with slicer 
activity. Messenger RNA molecule that displays perfect or 
near-perfect complementarity to the guide RNA are 
recognized and cleaved by Ago-2. Partial complementarity 
between a siRNA and target mRNA may in some cases 
repress translation or destabilize the transcripts if the 
binding mimics microRNA (miRNA) interactions with target 
sites (Figure 1). 
 
 
Figure 1 Molecular Mechanism of Gene Silencing By siRNA32 
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4. Therapeutic benefits of siRNA compared to 
conventional gene therapy (plasmid DNA)7, 33 
As the process of RNAi interferes with translation and not 
with DNA transcription, siRNA may not interact with 
chromosomal DNA. This lack of DNA interaction greatly 
reduces concerns about possible adverse gene alteration that 
might result from DNA-based gene therapy. The interaction 
of siRNA with mRNA and not with protein molecules also 
makes it possible to reduce the production of harmful 
proteins. siRNA is considered to be more potent as only a few 
siRNA molecules per cell are required to produce effective 
gene silencing. siRNA activation takes place in the cytoplasm 
and hence siRNA only needs to cross single barrier of cell 
membrane unlike viral vectors which have to cross multiple 
barriers such as nuclear membranes to reach cell genome. 
Moreover, conventional targets of traditional chemical drugs 
have been limited to certain classes of receptors, ion 
channels, and enzymes. Plasmid DNA can transfect during 
cell division phase only. However, siRNA can transfect cells 
both during cell resting and dividing phases, thus making it 
more effective. 
5. Applications of siRNA therapy 
5.1 Genetic diseases: 
siRNA provides great promise for successful treatment of a 
large number of genetic diseases. Preliminary studies 
revealed single nucleotide polymorphism4, 34 in mutant allele 
transcripts can be used as effective targets for RNAi. One of 
the challenging targets for siRNA therapeutics is the disease 
causing polyglutamine proteins encoded by the CAG repeat 
containing transcripts. Such repeats are found in several 
neurological diseases. Recently, siRNA has been 
systematically tested for their ability to discriminate wild 
type from mutant alleles for disorders related to superoxide 
dismutase (SOD1) and huntingtin (HTT). 
5.2 Viral diseases: 
Initial application of the RNAi technology had been directed 
in the treatment of infections caused by hepatitis B (HBV) 
and hepatitis C (HCV) viruses.  A significant knockdown 
(99%) of HBV core antigens was achieved in liver 
hepatocytes by using shRNA directed against them. Similarly, 
anti-HCV siRNA has shown to be effective in curing Huh-7.5 
cells bearing persistently replicating HCV replicons. 
Moreover, inhibition of HIV replication has been achieved in 
numerous human cell lines and primary cells including T 
lymphocytes and hematopoietic stem cell derived 
macrophages. 
5.3 Cancer: 
The use of RNAi as a part of cancer therapy has great 
potential in revolutionizing cancer treatment. However, 
inherent challenges for cancer are not different compared to 
other diseases.  
RNAi based cancer therapies include: 
i. Cessation of angiogenesis via inhibiting VEGF-
signaling,7-13 
ii. Inducing apoptosis via inhibiting WNT and NF-κB 
pathways; 
iii. Inhibiting EGFR, HER-2/NEU, telomerase, MDM2 
and p53 or Bcl-2 molecules. 
 
 
6. Delivery of siRNA4, 7, 35 
6.1 Challenges in siRNA delivery: 
The delivery target location of siRNA is the cytoplasm of the 
target cells. Although this is one barrier less than that 
required for delivering plasmid DNA (which requires 
crossing the nuclear membrane for entry into the cellular 
genome), delivering siRNA still remains a great challenge. 
The first concern is the stability of siRNA itself. Naked siRNA 
is more prone to degradation and has plasma half-life in 
minutes. Their relatively small size also leads to rapid 
clearance by kidney filtration after systemic injection. 
Together with siRNA’s negative charge that prevents its 
association with cell membrane, it's unlikely to simply use 
siRNA as a drug formulation. When formulated into a 
delivery vehicle, the stability of the delivery formulation is 
another issue. The siRNA loaded formulation has to escape 
from nonspecific uptake by the reticuloendothelial system 
(RES), especially the Kupffer cells in the liver and the 
macrophages in the spleen. Even if the siRNA stays in the 
blood circulation long enough, the siRNA formulation has to 
extravasate and gain access to the target tissue if the target is 
not blood cells or blood vessel cells (vascular endothelium). 
All the above is considered as the “kinetic barriers” which 
prevent the siRNA formulation from getting “access to the 
target cells”. The other category of barrier represents the 
“physical barrier”. Physical barriers are the hurdles that 
impede “the access of siRNA to the cytoplasm”. Initially, 
siRNA needs to cross the cell membrane. Most commonly 
used delivery strategy for macromolecules including siRNA is 
to take advantage of the receptor-mediated endocytosis. 
After endocytosis, siRNA will need to escape the endosome 
to reach the cellular cytoplasm where the RISC locates. 
Another challenge facing siRNA therapy is ‘immune 
stimulation’; this is recognition of siRNA duplex by the innate 
immune system. Introduction of too many siRNA molecules 
is found to result in nonspecific events. 
6.2 Strategies in overcoming hurdles involved in siRNA 
delivery 
6.2.1 siRNA delivery using vectors: 
6.2.1.1 Viral vectors35 
6.2.1.2 Non-viral vectors. 
A. Lipid based vesicular systems (lipoplexes) 
B. Polymer based vesicular systems (polyplexes)  
6.2.2 Physical delivery of siRNA, 
6.2.3 Chemical modifications of siRNA. 
6.2.1 siRNA delivery using vectors: 
6.2.1.1 Viral vectors:34, 35 
Viral vectors possess certain advantages and disadvantages 
which are as follows:  
Advantages: 
1. They have higher transfection efficiency, 
2. They show stable transfection, the phenomenon is 
useful for treating chronic conditions. 
Disadvantages of viral vectors: 
1. Susceptibility to immunostimulation, 
2. Limited carrying capacity of genetic material in 
terms of number of base pair units/ kilodalton, 
3. Chances of recombination, 
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4. High cost in formulation and processing, 
5. low scalability, 
6. Not useful in instances where stable transfection is 
not needed i.e. expression of genes during periodic 
remodeling following pathogenesis. Periodic remodeling 
during acute illness may be transient and may be regulated 
in a short period of time needing more temporary 
intervention. Hence, though high transfection efficiency and 
stable transfection, disadvantages of viral vectors led to 
increased strategic work for non-viral vectors such as 
lipoplexes and polyplexes. 
6.2.1.2 Non-viral vectors: 
Non-viral vectors are aimed to overcome following barriers 
during siRNA delivery: 
Kinetic barriers include: 
1. In vivo degradation of siRNA by plasma nucleases; 
2. Off target gene silencing (non-specific gene 
silencing). 
Physical barriers include: 
1. Repulsion by cellular plasma membrane (which is 
embedded by anionic components viz. heparin, 
peptidoglycans etc.) due to anionic charge on siRNA. 
2. Endosomal escape and cytoplasmic release. 
A. Lipid mediated siRNA Delivery35 
All kinetic and physical barriers to siRNA delivery are likely 
to be overcomed by formulations containing cationic lipid, 
especially cationic lipoplexes. These formulations help in 
efficient siRNA delivery by following mechanisms: 
 
i. Overcoming kinetic barriers (barrier to the transfer 
of siRNA in circulation to the target site): 
In vivo degradation of siRNA by plasma nucleases and 
mobile scavengers (macrophages) could be overcomed by 
complexing siRNA with functional cationic lipid having 
cationic lipid to siRNA charge ratio higher i.e p/n ratio 
(phosphorous to nitrogen ratio) greater than one so that net 
excess positive charge on the lipid surface (net cationic) 
could help in retaining siRNA molecules since these 
molecules are anionic. Off target gene silencing can be 
avoided by active and passive targeting. Active targeting 
includes tagging lipoplexes with moieties such as transferrin, 
asialoglycoprotein, integrin, folate for tumor targeting. 
PEGylating the surface of cationic lipoplexes increases 
stearic hindrance on the surface and prevents engulfment 
and scavenging by reticuloendothelial system. 
ii. Overcoming physical barriers (barrier to the entry 
into the target cell): 
Cationic lipoplexes accumulates to the target cell membrane 
and gets endocytosed into the cytoplasm due to the anionic 
nature of plasma membrane. Endosomal escape (Figure 2) 
and release of siRNA into the cytoplasm following 
endocytosis remain the critical parameter for siRNA delivery 
into the cytoplasm. Cationic lipids together with its fusogenic 
property and pH buffering tendency assist in endosomal 
escape and siRNA release in the cytoplasm. Various 
mechanisms of endosomal escape are as follows: 
a. Ion pair formation 
After endocytosis, cationic lipids form ion pairs with the 
anionic lipids in the endosome membrane and thus, 
destabilize the endosomal membrane by excluding the 
surface bound water. Electrostatic interaction between 
cationic lipid and anionic lipid could further promote the 
formation of the inverted hexagonal (HII) phase which then 
assist in endosomal escape37, 38. Lipids with small and/or less 
hydrophilic head group and bulky acyl or alkyl chains favor H 
II phase formation. Cationic lipid with a C18:2 alkyl chains 
showed higher delivery efficiency than the one with C18:1 
chain. DOTAP containing two C18:1 acyl chains, is commonly 
used for transfection. However, DSTAP, a close analog of 
DOTAP but with two C18:0 chains, is not commonly used. HII 
phase is an intermediate structure when two lipid bilayers 
fuse with each other. In the process of fusion, both bilayers 
are destabilized. Thus, the ion-pair formation between the 
cationic lipids in the lipoplex and the anionic lipids in the 
endosome membrane not only destabilizes the endosome 
membrane, but also promote de-assembly of the lipoplex.  
Ion- pair formation requires close contact of the lipids with 
opposite charges. PEGylation of liposomes or LPD may 
significantly reduce the interactions between the cationic 
lipids and the endosomal lipids due to stearic hindrance. 
PEGylation of the vector is often required to overcome the 
kinetic barriers. Cleavable PEG-lipid linker or acid labile PEG 
molecule design could be the answers to this problem. Many 
protein transduction domains contain arginine, and not 
lysine. It was showed that the presence of multiple 
guanidinium cations is important to their ion-pair formation 
in endosome that leads to efficient endosome escape. It was 
proposed that guanidinium cation containing delocalized 
positive charge can interact with an anionic group with 
delocalized negative charge. It is interesting to note that 
naturally occurring anionic groups in biological molecules, 
including phosphate, carboxyl and sulfate, all contain the 
delocalized negative charge which demonstrates the ion-pair 
formation between the delocalized positive charge of 
arginine and the delocalized negative charge of the 
phosphate group. The natural DNA condensing molecule in 
the sperm, i.e., protamine, is a polypeptide containing many 
arginine residues (Figure 3). 
 
Dhruvkumar M. Soni                                                                                     Journal of Drug Delivery & Therapeutics. 2020; 10(3-s):239-250 
ISSN: 2250-1177                                                                                  [243]                                                                                 CODEN (USA): JDDTAO 
 
Figure 2 Mechanisms of endosomal escape 
 
 
 
Figure 3 Ion pair effect in endosomal release38 
 
 
Polyarginine Polylysine 
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b.  Proton sponge effect 
Unlike lipoplex that relies on the fusogenic property of the 
lipid bilayer to mediate endosomal escape, polymeric 
carriers such as polyethyleneimine (PEI) are supposed to use 
the proposed “proton sponge” effect to enhance endosomal 
release of the endocytosed polyplex.39 
c.  Deassembly 
The siRNA complex must de-assemble sufficiently in the 
endosome or in the cytoplasm so that the released siRNA 
could access the RISC complex for gene silencing.  
Different types of lipid used in the formulation of lipoplexes 
are as follows:1, 35 
i. pH sensitive lipids Trigger sensitive lipids:35 
The mechanisms of pH-triggered endosomal destabilization 
include:  
1) Neutralization of negatively charged lipids in the bilayers 
via protonation leading to a lamellar to hexagonal phase 
transition. For eg. phosphatidylcholine and N-palmitoyl 
homocysteine (PHC). Upon exposure to lower pH, PHC 
undergoes a transition from a charged open form to an 
uncharged thiolactone ring form which destabilizes the 
bilayer and releases the encapsulated drug cargo.40 
2) Acid-catalyzed hydrolysis of bilayer-stabilizing lipids into 
destabilizing detergents or conical lipids. To circumvent 
potential problems due to the negatively charged surface of 
pH-sensitive liposome, cleavable liposomes with functional 
groups whose hydrolysis is catalyzed by acidic conditions 
have been designed. Different head groups, lipid chains, 
linker groups, and linkage configuration can be introduced. 
For example: acid sensitive vinyl ether linkage between head 
group and hydrocarbon chains41,42 (Figure 4). 
 
        
Figure 4 Acid and non - acid sensitive lipids 
 
ii. Temperature sensitive lipids: 
Lipids which are temperature sensitive and get destabilized 
at the body temperature are under clinical trials. 
iii. Charge reversal/charge switching lipids:43 
The charge-reversal lipid has a cationic ammonium head 
group to bind DNA, lipophilic acyl chains to form a bilayer, 
and benzyl esters at the terminus of the acyl chains for 
enzymatic hydrolysis (Figure 5). When cationic in charge, 
charge-reversal lipid binds to nucleic acid molecules and 
then releases nucleic acid when it is anionic. 
 
 
Figure 5 Charge reversible lipids 
 
iv. Reducible lipid:44 
Cytoplasm has relatively high concentrations of reductive 
species such as 10 mM glutathione and the enzymes such as 
thioredoxin and glutaredoxin. Once internalized into the cell, 
the lipoplex (liposomes loaded with siRNA) possessing a 
redox sensitive disulfide bond within its structure undergo S-
S cleavage. Hence, reduction of the disulfide bond affords 
degradation of the lipid followed by destabilization of the 
liposomal membrane and release of DNA (Figure 6).
 
Key:  
 Acid sensitive lipids with vinyl 
ether linkage:  (diplasmenylcholine 
and BCAT)  
 Non acid sensitive divinyl ether 
linkage lipid (DCAT). 
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Figure 6 Reducible lipid 
 
v. Mixed Lipids 
Lipids used for formulating lipoplexes are as follows: 
i. N(1-(2,3dioleyloxy) propyl) N, N, N-
trimethylammoniumchloride (DOTMP) used as Cationic lipid 
for siRNA transfection. ii. Helper lipids such as cholesterol 
and DOGS enhance lipoplex protection in the serum and 
increase transfection efficiency. iii. Fusogenic lipids such 
dioleoylphosphatidylethanolamine (DOPE) and 
dioleolylphosphatidylcholine (DOPC) assist in endosomal 
escape mechanism (Figure 7). 
   
             
                 Figure 7.1 Dioleoylphosphatidylethanolamine                         Figure 7.2 Dioleoylphosphatidylcholine  
 
Importance of fusogenic lipids (viz. DOPE): 
Di-unsaturation in the fusgenic lipid increases the fluidity 
and fusogenic tendency irrespective of the position of 
unsaturation in the molecule. Fusogenic lipids maintain the 
lamellar phase of the lipoplexes in the plasma which help in 
decreasing lipoplex interaction with plasma proteins. 
However, fusogenic lipids also undergo phase transition 
from lamellar phase to inverted hexagonal phase inside the 
endosome which then assist in enhancing its interaction 
with the endosomal membrane followed by siRNA release. 
vi.) Charged lipids45 
Cationic lipids are typically composed of three structural 
domains:  
i.  Cationic head group,  
ii.  Hydrophobic part and  
iii.  Linker between the two domains. 
Some examples of commercially available lipid reagents 
include  
N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethyl-ammonium 
chloride (DOTMA),  
2,3-dioleyloxy-N-(2(sperminecarboxamido)ethyl)-N,N-
dimethyl-1-propanaminiumtrifluoroacetate(DOSPA),1,2-
dioleoyl-3-trimethylammoniumpropane (DOTAP) and 
dioctadecylamido-glycylspermine (DOGS) (Figure 8). 
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Figure 8 Dioctadecyamidoglycylspermine (DOGS) 
I. Different methods employed in the manufacturing 
lipoplexes are categorized as follows:34 
1. Dehydration rehydration, 
2. Ether injection, 
3. Reverse phase evaporation; 
4. Detergent dialysis technique. 
General procedure for Lipoplex preparation using Film 
Rehydration Technique is as follows: 
1. Initially, small unilamellar cationic liposomes (SUV) were 
prepared from a 1:1 (mol. ratio) mixture of 1,2-dioleoyl-3-
(trimethylammonium) propane (DOTAP) and cholesterol 
(Chol), by extrusion of multilamellar liposomes (MLV).  
2. Lipids were dissolved in chloroform (CHCl3) and then 
dried under vacuum in a rotatory evaporator. 
3. The dried lipid films were hydrated with high purity water 
and then the resulting MLV thus formed were sonicated 
followed by its extrusion through two stacked polycarbonate 
filters of 50 nm pore diameter.  
4. The resulting liposomes (SUV) were then diluted with 
deionized water and filter-sterilized utilizing 0.22 μm pore 
diameter filters.  
5. Lipoplexes were prepared by sequentially mixing 
liposomes with siRNA and followed by vortexing. 
II. Characterization of cationic lipoplexes34, 46 
Cationic lipoplexes are characterized for following 
properties: 
1. Lipoplexes morphology:34,35 
Two fundamentally different types of models have been 
employed in order to interprete the cationic lipoplex 
structures which include an “external” model in which DNA 
is adsorbed onto the surface of cationic liposomes and an 
“internal” model in which the siRNA is surrounded or 
“coated” by a lipid envelope.   
Phase Behavior: 
Lamellar structure is confirmed to be present during the 
condensation and transport of the nucleic acid molecules 
whereas a more aggressive inverted hexagonal structure is 
formed upon its contact with the cell membrane. The 
appearance of the lipoplexes is often a highly ordered 
tubular structure when they are endocytosed by cells and 
assume perinuclear localization in these endosomes. Cryo-
electron images demonstrating the presence of such 
structures are shown in Figure 9. 
 
                            
Figure 9 Phase morphology 
 
 
 
Key: Schematic representation of 
(a) The lamellar structure (LC α) of cationic 
lipid/DNAlipoplexes, where the DNA rods are 
sandwiched between the lipid bilayers; 
(b) The inverted hexagonal structure (HC II), where 
DNA rods are coated withlipid monolayer arranged 
on a hexagonal lattice. 
 
Dhruvkumar M. Soni                                                                                     Journal of Drug Delivery & Therapeutics. 2020; 10(3-s):239-250 
ISSN: 2250-1177                                                                                  [247]                                                                                 CODEN (USA): JDDTAO 
2. Particle Size: 
Essentially particle size should be within the safe range 
which can be injectable in vivo. However, larger sized 
lipoplexes usually show high transfection efficiency due to 
larger surface available to contact with plasma membrane 
for endocytosis and again larger surface of the endosomal 
membrane remaining in contact with the liposomal 
membrane. Particle size increases with increase in lipid to 
siRNA ratio too. 
3. Zeta potential measurements: 
Zeta potential measurement is one of the vital 
characterization parameters of cationic lipoplexes. Positive 
zeta potential measurement implies net positive charge of 
cationic liposome to siRNA ratio and siRNA embedded inside 
the core of lipoplexes whereas negative zeta potential value 
indicates presence of siRNA on the surface of liposomes. 
4. Surface topological profile: 
Scanning electron microscopy using negative staining using 
phosphotungstenic acid is generally performed. Cryo-
fracture electron microscopy technique is also been 
performed for surface morphological measurement. 
5. Target cell transfection efficiency: 
Transfection efficiency of cationic lipoplexes is generally 
characterized by confocal laser scanning microscopy. The 
expression of green fluorescence peptide is quantitatively 
measured by measuring the intensity of fluorescence. 
6.  Cell viability studies: 
Cell viability studies are generally performed using 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide 
(MTT) assay.  MTT gets reduced in the mitochondria of 
viable cells to a blue formazan product which absorbs 
maximally at 570 nm. Greater the color intensity of formazan 
crystals under U.V., higher is the viability of the cells. 
7.  1H-NMR studies: 
 1H-NMR studies help in understanding the presence of 
physical bonds formed between siRNA and cationic 
lipoplexes. 
8.  Gel permeation studies: 
GEL permeation studies help in quantitating the amount of 
siRNA remaining unbound within the lipoplexes. 
9.   Gel retardation assay (GRA): 
GRA also assist in quantitating the amount of free siRNA. 
Certain polypeptides have tendency to bind to naked siRNA. 
The resultant increase in molecular size of siRNA 
polypeptide complex retards the moment of the complex 
within the gel system. 
III. Optimization of lipoplexes formulation:34, 36, 37 
Optimization of lipoplex formulation is a prerequisite 
exercise for enhancing lipoplex properties which include: 
1. Transfection efficiency, 
2. siRNA formulation stability, 
3. Degradation of siRNA in circulation (plasma), 
4. Off-target toxicity, 
5. Delivery efficiency and endosomal escape, 
6. Cytotoxicity of cationic lipoplexes; 
7.         Charge density on the lipoplex surface. 
Following factors needed to be optimized for lipoplex 
mediated siRNA delivery include: 
1. lipoplex morphology:35 
It is proposed that the absence of a propensity for transition 
to the HC II phase may result in a lower transfection 
potential compared to the lipoplexes that exhibit a higher-
order inverted hexagonal structures. The difference of 
transfection efficiency between LC α phase and HC II phase 
comes from the fact that HCII lipoplexes fuse and release 
nucleic acid when in contact with anionic vesicles which are 
cell-free models of cellular membranes, in particular, anionic 
endosomal vesicles, but LC α lipoplexes remain stable when 
they come in contact with vesicle membranes confirmed by 
optical microscopy. On the other hand, HC II phase facilitates 
the interaction with the cell membrane and/or enables it to 
escape from the endosome.  
2. Lipoplex size, plasma stability, transfection efficiency 
and endosomal escape. 
Another parameter of morphology affecting transfection 
efficiency is lipoplex size. 
Formulation stability:  
Stability of siRNA depends on the charge ratio of lipid to 
DNA. 
Transfection efficiency and particle size inhibition by serum. 
Lipofection inhibition by serum is largely due to the 
tendency of serum in preventing lipoplex size growth which 
may be overcomed by using large, stable lipoplexes. 
Lipoplexes size of less than 250 nm measured by dynamic 
light scattering showed efficient transfection efficiency in 
cells in absence of serum. Conversely, lipoplexes of over 700 
nm mean diameter induce efficient transfection in the 
presence or absence of serum.  
Endosomal escape: 
Large lipoplexes size is more efficient to transfer gene 
because large particles are easily taken up by cells leading to 
the formation of large intracellular vesicles which are more 
easily disrupted, thus releasing siRNA into the cytoplasm. In 
addition, the advantageous effect of large particles upon 
lipofection has been attributed to maximum contact with 
cells, increased phagocytic activity accompanied by 
endosomal escape and faster sedimentation and better 
cellular trafficking. 
Overcoming cell cytotoxicity by cationic lipoplexes: 
Cationic lipoplexes induced a significant cytotoxicity towards 
HeLa cells, B16BL6 cells and RGC-6 cells compared to 
cationic lipid alone and the cytotoxicity increases as the 
cationic lipid content in the lipoplex increased. Hence, 
anionic polymers are incorporated for decreasing toxicity 
and enhancing in vivo delivery of siRNA complexed with 
cationic liposome. Addition of anionic polymers into siRNA 
lipoplexes lead to efficient lipoplexes mediated delivery. 
Divalent calcium ions are used to complex siRNA and anionic 
polymer within the cationic lipoplexes.36, 38 
B. Polymer mediated siRNA delivery (polyplexes)34, 39 
Polymer-based delivery systems have been extensively used 
for plasmid DNA and more recently for siRNA. As with lipid-
based delivery systems, polymeric delivery of siRNA usually 
involves a cationic moiety as a core component of polyplex. 
Distinct features of polymers used for siRNA delivery 
include:34 
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i. Cationic polymeric delivery system provides higher 
simplicity for the formulation of siRNA and polymeric 
complexes (polyplexes), 
ii. Unlike cationic lipoplexes, which require several 
processing steps in formulation, cationic polymers usually 
form complex with negatively charged siRNA upon simple 
mixing, 
iii. Polyplexes are soluble in water;  
iv. However, cationic polyplexes cannot destabilize 
endosomal membrane by surfactant like activity due to lack 
of hydrophobic domain. 
Cationic polymers are generally classified into synthetic and 
natural polymers.39 
 Synthetic polymers include: 
Polyethyleneimine (PEI), poly-L-lysine (PLL) and 
cyclodextrin-based polycations. 
 Natural polymers include: 
Chitosan, atelocollagen and cationic polypeptides. 
III.  Biodegradable polymers39 include: 
Polylactide-co-glycolide. 
i.)  Synthetic polymers  
Polyethyleneimine (PEI)40 
1. PEI is extensively used cationic polymer, has a wide range 
of molecular weights and multiple protonable amino groups 
leading to a higher cationic charge at physiological pH.  
2. Complexation of nucleic acids with PEI is achieved by 
electrostatic interactions between the positively charged 
amino groups of PEI and the negatively charged phosphate 
groups of siRNA. 
3. The advantage of using PEI over other polymers is the high 
transfection efficiency due to proton sponge effect”.  PEIs 
have buffering capability in the low pH of the endosome, 
thereby releasing nucleic acids into the cytoplasm. The 
magnitude of this effect depends on charge density in the 
lipoplexes surfaces. 
4. To reduce the cytotoxicity induced by high molecular 
weight PEI and to increase serum nuclease resistance, 
various approaches are employed which include:  
In one of the studies, wide range of PEG moieties was 
introduced to PEI for production of block copolymers. 
Increasing the hydrophilicity of PEG is expected to reduce 
the toxicity of the copolymer, improve the poor solubility of 
the PEI and siRNA complexes and help introduce degradable 
bonds by reaction with primary amines in the PEI. Moreover, 
the PEG moieties can form a shielding layer that protects the 
polyplex structure against undesirable interactions with 
degradation enzymes or proteins in the bodily environment. 
With the PEG derivatives of PEI, the chain length and graft 
density of PEG were found to strongly influence siRNA 
condensation and stability. PLL-graft-PEG copolymers have 
been used to increase the circulation time of siRNA in vivo. 
Disadvantages of PEI: 
A problem with the use of PEI is appreciable cytotoxicity. PEI 
has been shown to induce cell death in a variety of cell lines 
through cellular mechanisms such as necrosis and apoptosis. 
The cytotoxicity of PEI tends to increase at high molecular 
weights and with increasing branching units. The removal of 
uncomplexed PEI after complexation reaction with siRNA 
was shown to be effective in reducing the toxicity of PEI. 
Purified complexes without free PEI had to be given at 
increased concentrations to achieve high transfection levels, 
but it also ensures improved toxicity profiles. 
ii.) Natural polymers39 
Chitosan41 
Chitosan is a naturally occurring biocompatible, 
biodegradable polycation with low toxicity, thus could serve 
a promising carrier for delivering siRNA. Owing to the 
interaction of anionic siRNA and cation chitosan, siRNA can 
be complexed and loaded into chitosan nanoparticles. 
Chitosan has been used successfully to form complex with 
siRNA against green fluorescence protein (GFP). The 
spherical and stable chitosan siRNA nanoparticles with 83 - 
94% complex efficiency can be formulated under mild 
electrostatic interaction. Nearly 80% gene silencing 
efficiency of chitosan-siRNA nanoparticles could be achieved. 
iii.) Biodegradable polymers42 
Polylactide-co-glycolide: 
Poly(DL-lactide-co-glycolide) (PLGA) is an FDA-approved 
biodegradable polymer. PLGA nanoparticle has been used as 
gene vector for siRNA. 
6.2.2 Physical methods of siRNA delivery39 
Physical method is another strategy for introducing siRNA 
into cells and tissues.  
Advantages: 
1) Physical methods may avoid the possible 
nonspecific immune stimulations which might arise in some 
of chemical delivery systems.  
2) Moreover, owing to their non-invasiveness and 
relative convenience for clinical application, there are 
increasing interests in physical methods for delivery of 
siRNA. Various physical methods include hydrodynamic 
injection, particle bombardment and electroporation, ultra 
sound and direct injection into the cell. Electroporation has 
been most frequently studied to stimulate the cellular and 
localized in vivo delivery of siRNA through electric pulses. 
 
6.2.3 Chemical Modifications26 
To enhance the stability of siRNA for prolonged circulation in 
vivo, chemical modification of siRNA has been attempted. 
Chemical modification increases gene expression in liver by 
preventing siRNA phagocytosis. Chemical modifications at 
particular position reduce off target gene silencing and 
increase the efficiency of gene silencing. Various positions 
within the siRNA duplex have been chemically replaced or 
modified to provide nuclease resistance. One of the common 
approaches is replacement of the phosphodiester (PO4) 
group with phosphothioate (PS) at the 3'-end. Moreover, the 
introduction of an O-methyl group (2'-O-M), a fluoro (2'-F) 
group, or a 2-methoxyethyl (2'-O-MOE) group resulted in 
prolonged half-lives and RNAi activities in cultured cells and 
plasma.  
7. Evidence of improved siRNA mediated 
therapeutic efficacy: 
Vast literature reports demonstrating superior advantages of 
siRNA are documented. Some of these reports are described 
here briefly. For instance, siRNA loaded cationic liposomes 
were developed with new polyarginine-conjugated PEG-
lipid.43 The cationic liposome formulation using a new PEG-
lipid (PLR–PEG) showed not only enhanced intracellular 
Dhruvkumar M. Soni                                                                                     Journal of Drug Delivery & Therapeutics. 2020; 10(3-s):239-250 
ISSN: 2250-1177                                                                                  [249]                                                                                 CODEN (USA): JDDTAO 
delivery of siRNA but also decreased cytotoxicity on H4II-E 
and HepG2 cell lines. The siRNA delivered by new cationic 
liposomes using PLR–PEG was effective in reducing the 
protein expression levels of the gene. The results suggested 
that the cationic liposomes could be used for efficient 
delivery of siRNA therapeutics. In another study, anti-
angiogenic therapy via cationic liposome-mediated systemic 
siRNA delivery was established.44 In this study, various 
batches of polyethylene glycol (PEG)-coated cationic 
lipoplexes were prepared and subsequently screened for the 
avidity of these siRNA-lipoplexes upon angiogenic tumor 
vessels. Lipoplex having a lipid composition of DC-6-
14/POPC/CHOL/DOPE/mPEG2000-DSPE=20/30/30/20/5 
(molar ratio) and a charge ratio of cationic liposome and 
siRNA = 3.81 (+/-), showed a higher binding index to newly 
formed blood vessels. However, in another study, ultra-
deformable cationic liposomes were developed for delivery 
of small interfering RNA into human primary melanocytes.45 
Blockade of the expression of a specific Myosin Va exon F 
containing isoform that is physiologically involved in 
melanosome transport in human melanocytes was intended. 
Ultra-deformable cationic liposomes (UCL) to deliver siRNA 
in hard to transfect human primary melanocytes were 
prepared and investigated in this study. 
Additionally, a novel cholesterol derivatized cationic 
liposomes were developed for enhanced delivery of siRNA 
was been developed.46 Two cholesterol derivatives, 
cholesteryloxypropane-1-amine (COPA) and cholesteryl-2-
aminoethylcarbamate (CAEC) were evaluated. Uptake 
visualization using fluorescent labeled COPA and CAEC 
lipoplexes was studied. The presence of serum demonstrated 
varied effects on the cellular delivery of siRNA when siRNA 
was complexed to different cationic liposomes. CAEC based 
liposomes showed significantly reduced cellular delivery of 
siRNA in serum containing media as compared to serum free 
media. However, COPA-based liposome (COPA-L) showed 
serum enhanced delivery of siRNA in Hepal-6, A549 and Hela 
cell lines. In a separate study, anionic polymers were used for 
decreased toxicity and enhanced in vivo delivery of siRNA 
complexed with cationic liposomes.38 In this study a new 
vector of cytokine targeted siRNA based on cationic lipid was 
developed for intravenous injection. Weekly injections of 
siRNA targeted to IL-1, IL-6 or IL-18 delivered in 
combination and formulated with cationic liposomes 
significantly reduced all pathological rheumatoid arthritis 
features. siRNA vector was formed by mixing lipopolyamine-
containing cationic liposome with premixed solution of 
siRNA and plasmid DNA (p-DNA) acting as an anionic 
“cargo”.  Addition of pDNA cargo to siRNA prior to forming 
the complex with cationic liposome, led to enhanced gene 
silencing efficiency with reduced siRNA concentration. 
However, addition of DNA molecule in siRNA lipoplexes will 
not be acceptable in a clinical application since pDNA is a 
molecule that contains coding sequences. In this report, 
feasibility study was performed to replace pDNA by an 
anionic polymer that would be clinically approvable. Thus, 
siRNA lipoplexes with anionic polymers were prepared and 
their gene silencing efficiency as well as their 
physicochemical characteristics were evaluated. When added 
to siRNA lipoplexes, these anionic polymers increased their 
gene silencing efficiency. Upon i.v. injection in mice, siRNA 
lipoplexes prepared with polyglutamate led to significantly 
increased recovery of siRNA in liver and lung compared with 
lipoplexes without polymer. 
8. Conclusion 
Gene silencing by RNAi mechanism represents one of the 
most successful means of achieving gene therapy against 
genetic disorders. Silencing of pathological genes by small 
interference RNA (siRNA) is observed as an efficient means 
of treating diseases which have been originated due to 
genetic malfunctions. Even though siRNA empowers 
researchers with its efficient gene silencing capabilities, its 
delivery to the target site has always been an issue. Viral and 
non – viral vectors are developed to overcome gene delivery 
problems. However, non – viral vectors are highly explored 
because of its advantages of safety and efficacy over viral 
vectors. Non – viral vectors include polymeric and lipidic 
carriers. However, lipidic carriers have emerged as most 
superior and compatible delivery carriers for site specific 
siRNA delivery. Lipoplexes have been widely explored as 
pioneer lipidic vesicles for siRNA delivery and have proved 
to be efficient not only in overcoming delivery barriers for 
siRNA but also have showed to be beneficial in achieving 
higher loading both for siRNA and other molecules which 
could be beneficial when used in combination. Lipoplexes 
can also be surface functionalized via pegylation and active 
targeted ligands for achieving optimum pharmacokinetic and 
tissue specific siRNA delivery. Hence, siRNA mediated gene 
therapy embarks prominent means of achieving efficient 
treatment modality for variety of genetic disorders.  
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